FDA Inspection 1201325 — Dana-Farber Cancer Institute, Office of Human Research Studies IRB
The FDA completed an inspection of Dana-Farber Cancer Institute, Office of Human Research Studies IRB on February 23, 2023 in Brookline, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 23, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Bioresearch Monitoring
- Location
- Brookline, MA (United States)
Additional Details
IRB